Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression ≥50%....

Descripción completa

Detalles Bibliográficos
Autores principales: Gogishvili, Miranda, Melkadze, Tamar, Makharadze, Tamta, Giorgadze, Davit, Dvorkin, Mikhail, Penkov, Konstantin, Laktionov, Konstantin, Nemsadze, Gia, Nechaeva, Marina, Rozhkova, Irina, Kalinka, Ewa, Gessner, Christian, Moreno-Jaime, Brizio, Passalacqua, Rodolfo, Li, Siyu, McGuire, Kristina, Kaul, Manika, Paccaly, Anne, Quek, Ruben G. W., Gao, Bo, Seebach, Frank, Weinreich, David M., Yancopoulos, George D., Lowy, Israel, Gullo, Giuseppe, Rietschel, Petra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671806/
https://www.ncbi.nlm.nih.gov/pubmed/36008722
http://dx.doi.org/10.1038/s41591-022-01977-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671806/
https://www.ncbi.nlm.nih.gov/pubmed/36008722
http://dx.doi.org/10.1038/s41591-022-01977-y

Ejemplares similares